Literature DB >> 27306910

Cancer Incidence in First- and Second-Degree Relatives of BRCA1 and BRCA2 Mutation Carriers.

Haley Streff1, Jessica Profato2, Yuanqing Ye3, Denise Nebgen4, Susan K Peterson5, Claire Singletary6, Banu K Arun2, Jennifer K Litton7.   

Abstract

BACKGROUND: Mutations in the BRCA1 and BRCA2 genes are associated with increased risk of breast, ovarian, and several other cancers. The purpose of the present study was to evaluate the incidence of cancer in first- and second-degree relatives of BRCA mutation carriers compared with the general population.
MATERIALS AND METHODS: A total of 1,086 pedigrees of BRCA mutation carriers was obtained from a prospectively maintained, internal review board-approved study of persons referred for clinical genetic counseling at the University of Texas MD Anderson Cancer Center. We identified 9,032 first- and second-degree relatives from 784 pedigrees that had demonstrated a clear indication of parental origin of mutation. Standardized incidence ratios (SIRs) were used to compare the observed incidence of 20 primary cancer sites to the expected incidence of each cancer based on the calculated risk estimates according to each subject's age, sex, and ethnicity.
RESULTS: BRCA1 families had increased SIRs for breast and ovarian cancer (p < .001) and decreased SIRs for kidney, lung, prostate, and thyroid cancer and non-Hodgkin's lymphoma (p < .001). BRCA2 families had increased SIRs for breast, ovarian, and pancreatic cancer (p < .001) and decreased SIRs for kidney, lung, thyroid, and uterine cancer and non-Hodgkin's lymphoma (p < .0025). Analysis of only first-degree relatives (n = 4,099) identified no decreased SIRs and agreed with the increased SIRs observed in the overall study population.
CONCLUSION: We have confirmed previous reports of an association between breast, ovarian, and pancreatic cancers with BRCA mutations. Additional research to quantify the relative risks of these cancers for BRCA mutation carriers can help tailor recommendations for risk reduction and enhance genetic counseling. IMPLICATIONS FOR PRACTICE: BRCA gene mutations have been well described to carry an increased risk of both breast and ovarian cancer. However, the implications and risks of other cancers continues to be investigated. Evaluating the risks for other cancers further is key in identifying and managing risk reduction strategies. ©AlphaMed Press.

Entities:  

Keywords:  BRCA; Breast cancer; Familial cancers; Genetic counseling; Ovarian cancer; Pancreatic cancer

Mesh：

Year:  2016        PMID： 27306910      PMCID： PMC4943383          DOI： 10.1634/theoncologist.2015-0354

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


  20 in total

1.  Accuracy of cancer family histories: comparison of two breast cancer syndromes.

Authors:  Katherine A Schneider; Lisa M DiGianni; Andrea Farkas Patenaude; Neil Klar; Jill E Stopfer; Kathleen A Calzone; Frederick P Li; Barbara L Weber; Judy E Garber
Journal:  Genet Test       Date:  2004

2.  Cancer risks in BRCA2 families: estimates for sites other than breast and ovary.

Authors:  C J van Asperen; R M Brohet; E J Meijers-Heijboer; N Hoogerbrugge; S Verhoef; H F A Vasen; M G E M Ausems; F H Menko; E B Gomez Garcia; J G M Klijn; F B L Hogervorst; J C van Houwelingen; L J van't Veer; M A Rookus; F E van Leeuwen
Journal:  J Med Genet       Date:  2005-09       Impact factor: 6.318

3.  Cancer risks in BRCA2 mutation carriers.

Authors: 
Journal:  J Natl Cancer Inst       Date:  1999-08-04       Impact factor: 13.506

4.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

Authors:  D Ford; D F Easton; M Stratton; S Narod; D Goldgar; P Devilee; D T Bishop; B Weber; G Lenoir; J Chang-Claude; H Sobol; M D Teare; J Struewing; A Arason; S Scherneck; J Peto; T R Rebbeck; P Tonin; S Neuhausen; R Barkardottir; J Eyfjord; H Lynch; B A Ponder; S A Gayther; M Zelada-Hedman
Journal:  Am J Hum Genet       Date:  1998-03       Impact factor: 11.025

5.  Risk of cancer at sites other than the breast in Swedish families eligible for BRCA1 or BRCA2 mutation testing.

Authors:  J Lorenzo Bermejo; K Hemminki
Journal:  Ann Oncol       Date:  2004-12       Impact factor: 32.976

6.  Cancer Incidence in BRCA1 mutation carriers.

Authors:  Deborah Thompson; Douglas F Easton
Journal:  J Natl Cancer Inst       Date:  2002-09-18       Impact factor: 13.506

7.  Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program.

Authors:  Marcia S Brose; Timothy R Rebbeck; Kathleen A Calzone; Jill E Stopfer; Katherine L Nathanson; Barbara L Weber
Journal:  J Natl Cancer Inst       Date:  2002-09-18       Impact factor: 13.506

8.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.

Authors:  Y Miki; J Swensen; D Shattuck-Eidens; P A Futreal; K Harshman; S Tavtigian; Q Liu; C Cochran; L M Bennett; W Ding
Journal:  Science       Date:  1994-10-07       Impact factor: 47.728

9.  The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers.

Authors:  J Iqbal; A Ragone; J Lubinski; H T Lynch; P Moller; P Ghadirian; W D Foulkes; S Armel; A Eisen; S L Neuhausen; L Senter; C F Singer; P Ainsworth; C Kim-Sing; N Tung; E Friedman; M Llacuachaqui; S Ping; S A Narod
Journal:  Br J Cancer       Date:  2012-10-25       Impact factor: 7.640

10.  Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study.

Authors:  C M Phelan; J Iqbal; H T Lynch; J Lubinski; J Gronwald; P Moller; P Ghadirian; W D Foulkes; S Armel; A Eisen; S L Neuhausen; L Senter; C F Singer; P Ainsworth; C Kim-Sing; N Tung; M Llacuachaqui; G Chornokur; S Ping; S A Narod
Journal:  Br J Cancer       Date:  2013-11-28       Impact factor: 7.640
View more
  20 in total

Review 1.  Inherited pancreatic cancer.

Authors:  Fei Chen; Nicholas J Roberts; Alison P Klein
Journal:  Chin Clin Oncol       Date:  2017-12

2.  Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).

Authors:  Valentina Silvestri; Goska Leslie; Daniel R Barnes; Bjarni A Agnarsson; Kristiina Aittomäki; Elisa Alducci; Irene L Andrulis; Rosa B Barkardottir; Alicia Barroso; Daniel Barrowdale; Javier Benitez; Bernardo Bonanni; Ake Borg; Saundra S Buys; Trinidad Caldés; Maria A Caligo; Carlo Capalbo; Ian Campbell; Wendy K Chung; Kathleen B M Claes; Sarah V Colonna; Laura Cortesi; Fergus J Couch; Miguel de la Hoya; Orland Diez; Yuan Chun Ding; Susan Domchek; Douglas F Easton; Bent Ejlertsen; Christoph Engel; D Gareth Evans; Lidia Feliubadalò; Lenka Foretova; Florentia Fostira; Lajos Géczi; Anne-Marie Gerdes; Gord Glendon; Andrew K Godwin; David E Goldgar; Eric Hahnen; Frans B L Hogervorst; John L Hopper; Peter J Hulick; Claudine Isaacs; Angel Izquierdo; Paul A James; Ramunas Janavicius; Uffe Birk Jensen; Esther M John; Vijai Joseph; Irene Konstantopoulou; Allison W Kurian; Ava Kwong; Elisabetta Landucci; Fabienne Lesueur; Jennifer T Loud; Eva Machackova; Phuong L Mai; Keivan Majidzadeh-A; Siranoush Manoukian; Marco Montagna; Lidia Moserle; Anna Marie Mulligan; Katherine L Nathanson; Heli Nevanlinna; Joanne Ngeow; Liene Nikitina-Zake; Kenneth Offit; Edith Olah; Olufunmilayo I Olopade; Ana Osorio; Laura Papi; Sue K Park; Inge Sokilde Pedersen; Pedro Perez-Segura; Annabeth H Petersen; Pedro Pinto; Berardino Porfirio; Miquel Angel Pujana; Paolo Radice; Johanna Rantala; Muhammad U Rashid; Barak Rosenzweig; Maria Rossing; Marta Santamariña; Rita K Schmutzler; Leigha Senter; Jacques Simard; Christian F Singer; Angela R Solano; Melissa C Southey; Linda Steele; Zoe Steinsnyder; Dominique Stoppa-Lyonnet; Yen Yen Tan; Manuel R Teixeira; Soo H Teo; Mary Beth Terry; Mads Thomassen; Amanda E Toland; Sara Torres-Esquius; Nadine Tung; Christi J van Asperen; Ana Vega; Alessandra Viel; Jeroen Vierstraete; Barbara Wappenschmidt; Jeffrey N Weitzel; Greet Wieme; Sook-Yee Yoon; Kristin K Zorn; Lesley McGuffog; Michael T Parsons; Ute Hamann; Mark H Greene; Judy A Kirk; Susan L Neuhausen; Timothy R Rebbeck; Marc Tischkowitz; Georgia Chenevix-Trench; Antonis C Antoniou; Eitan Friedman; Laura Ottini
Journal:  JAMA Oncol       Date:  2020-08-01       Impact factor: 31.777

3.  Outcome of Pancreatic Cancer Surveillance Among High-Risk Individuals Tested for Germline Mutations in BRCA1 and BRCA2.

Authors:  Amethyst Saldia; Sara H Olson; Pamela Nunes; Xiaolin Liang; Marguerite L Samson; Erin Salo-Mullen; Vanessa Marcell; Zsofia K Stadler; Peter J Allen; Kenneth Offit; Robert C Kurtz
Journal:  Cancer Prev Res (Phila)       Date:  2019-07-23

4.  Identification of Important Modules and Biomarkers in Breast Cancer Based on WGCNA.

Authors:  Zelin Tian; Weixiang He; Jianing Tang; Xing Liao; Qian Yang; Yumin Wu; Gaosong Wu
Journal:  Onco Targets Ther       Date:  2020-07-12       Impact factor: 4.147

Review 5.  Does thyroid dysfunction increase the risk of breast cancer? A systematic review and meta-analysis.

Authors:  Y Fang; L Yao; J Sun; R Yang; Y Chen; J Tian; K Yang; L Tian
Journal:  J Endocrinol Invest       Date:  2017-05-17       Impact factor: 4.256

6.  Expanding the spectrum of germline variants in cancer.

Authors:  Abdul K Siraj; Tariq Masoodi; Rong Bu; Sandeep Kumar Parvathareddy; Ismail A Al-Badawi; Nasser Al-Sanea; Luai H Ashari; Alaa Abduljabbar; Samar Alhomoud; Saif S Al-Sobhi; Asma Tulbah; Dahish Ajarim; Khalid Alzoman; Muna Aljuboury; Hussam Bin Yousef; Mohammed Al-Dawish; Fouad Al-Dayel; Fowzan S Alkuraya; Khawla S Al-Kuraya
Journal:  Hum Genet       Date:  2017-10-03       Impact factor: 4.132

Review 7.  AGA Clinical Practice Update on Colorectal and Pancreatic Cancer Risk and Screening in BRCA1 and BRCA2 Carriers: Commentary.

Authors:  Sonia S Kupfer; Samir Gupta; Jeffrey N Weitzel; Jewel Samadder
Journal:  Gastroenterology       Date:  2020-04-23       Impact factor: 22.682

8.  Double heterozygotes of BRCA1/BRCA2 and mismatch repair gene pathogenic variants: case series and clinical implications.

Authors:  Ido Laish; Eitan Friedman; Gili Levi-Reznick; Inbal Kedar; Lior Katz; Zohar Levi; Naama Halpern; Shani Parnasa; Aasem Abu-Shatya; Elizabeth Half; Yael Goldberg
Journal:  Breast Cancer Res Treat       Date:  2021-06-04       Impact factor: 4.872

9.  The Relationship of Mutation Carriage of BRCA1/2 and Family History in Triple-Negative Breast Cancer: Experience from a Diagnostic Center in Turkey.

Authors:  Neslihan Duzkale; Olcay Kandemir
Journal:  Eur J Breast Health       Date:  2021-03-31

10.  A novel germline BRCA1 mutation identified in a family with hereditary breast and ovarian cancer syndrome.

Authors:  Yanmei Wu; Xiaodong Pan; Juan Dou; Quan Zhang; Yuantong Li; Yuan Sheng; Xishui Liu
Journal:  Clin Med Insights Oncol       Date:  2021-07-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.